Stock Analysis on Net

Biogen Inc. (NASDAQ:BIIB)

This company has been moved to the archive! The financial data has not been updated since October 25, 2022.

Analysis of Profitability Ratios
Quarterly Data

Microsoft Excel

Profitability Ratios (Summary)

Biogen Inc., profitability ratios (quarterly data)

Microsoft Excel
Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017
Return on Sales
Gross profit margin 77.15% 77.34% 77.95% 80.79% 82.52% 83.95% 85.49% 86.57% 87.65% 87.97% 87.47% 86.40% 85.97% 85.59% 85.72% 86.50% 86.12% 86.43% 86.57% 86.72%
Operating profit margin 32.36% 26.64% 22.90% 25.87% 17.32% 18.94% 29.39% 33.84% 46.68% 50.93% 51.03% 48.98% 47.13% 46.90% 42.40% 43.77% 44.67% 45.58% 46.49% 43.54%
Net profit margin 27.64% 19.37% 13.40% 14.17% 13.93% 16.40% 23.89% 29.76% 35.63% 40.91% 40.76% 40.96% 37.91% 37.62% 33.79% 32.93% 24.08% 23.06% 23.54% 20.69%
Return on Investment
Return on equity (ROE) 22.42% 17.34% 12.90% 14.28% 14.82% 17.84% 28.19% 37.39% 47.24% 52.41% 46.85% 44.13% 38.55% 40.87% 33.74% 33.98% 23.15% 24.21% 21.09% 20.13%
Return on assets (ROA) 11.53% 8.21% 6.14% 6.52% 6.49% 7.84% 12.63% 16.25% 20.38% 23.23% 22.51% 21.62% 19.63% 20.14% 17.65% 17.52% 12.50% 12.39% 11.36% 10.73%

Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).

Profitability ratio Description The company
Gross profit margin Gross profit margin indicates the percentage of revenue available to cover operating and other expenditures. Biogen Inc. gross profit margin ratio deteriorated from Q1 2022 to Q2 2022 and from Q2 2022 to Q3 2022.
Operating profit margin A profitability ratio calculated as operating income divided by revenue. Biogen Inc. operating profit margin ratio improved from Q1 2022 to Q2 2022 and from Q2 2022 to Q3 2022.
Net profit margin An indicator of profitability, calculated as net income divided by revenue. Biogen Inc. net profit margin ratio improved from Q1 2022 to Q2 2022 and from Q2 2022 to Q3 2022.

Profitability ratio Description The company
ROE A profitability ratio calculated as net income divided by shareholders’ equity. Biogen Inc. ROE improved from Q1 2022 to Q2 2022 and from Q2 2022 to Q3 2022.
ROA A profitability ratio calculated as net income divided by total assets. Biogen Inc. ROA improved from Q1 2022 to Q2 2022 and from Q2 2022 to Q3 2022.

Gross Profit Margin

Biogen Inc., gross profit margin calculation (quarterly data)

Microsoft Excel
Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017
Selected Financial Data (US$ in thousands)
Gross profit 2,039,000 2,105,100 1,777,900 2,073,700 2,267,100 2,315,300 2,215,900 2,361,900 2,927,000 3,270,500 3,080,000 3,224,200 3,170,100 3,140,400 2,887,800 3,037,800 2,978,200 2,935,500 2,685,100 2,797,800 2,707,800 2,712,200 2,426,100
Revenue 2,508,500 2,589,100 2,531,800 2,733,800 2,778,900 2,775,000 2,694,000 2,852,600 3,376,100 3,681,600 3,534,300 3,671,300 3,600,100 3,616,700 3,489,800 3,526,300 3,439,000 3,356,500 3,131,100 3,307,000 3,077,800 3,078,400 2,810,700
Profitability Ratio
Gross profit margin1 77.15% 77.34% 77.95% 80.79% 82.52% 83.95% 85.49% 86.57% 87.65% 87.97% 87.47% 86.40% 85.97% 85.59% 85.72% 86.50% 86.12% 86.43% 86.57% 86.72%
Benchmarks
Gross Profit Margin, Competitors2
AbbVie Inc. 69.62% 70.48% 69.53% 68.96% 67.72% 65.62% 64.82% 66.41% 68.74% 73.56% 77.43% 77.64%
Amgen Inc. 73.99% 74.00% 73.30% 73.44% 74.00% 73.97% 74.37% 74.59% 75.55% 77.15% 78.90% 80.38%
Bristol-Myers Squibb Co. 78.82% 79.13% 79.62% 78.57% 76.92% 75.88% 74.42% 72.31% 71.18% 69.47% 68.02% 69.10%
Eli Lilly & Co. 75.61% 75.98% 74.40% 74.18% 74.85% 74.27% 75.88% 77.66% 78.26% 78.67% 79.22% 78.85%
Gilead Sciences Inc. 74.31% 75.30% 75.50% 75.56% 80.23% 79.90% 80.32% 81.23% 78.72% 78.25% 79.06% 78.86%
Johnson & Johnson 67.43% 67.86% 67.97% 68.16% 67.51% 67.00% 66.24% 65.58% 65.68% 65.66% 66.15% 66.42%
Merck & Co. Inc. 70.49% 70.41% 70.72% 72.02% 67.95% 67.48% 66.99% 67.74% 71.23% 70.06% 70.11% 69.87%
Pfizer Inc. 65.53% 62.18% 60.35% 62.08% 65.28% 70.96% 76.46% 79.26% 80.47% 80.19% 80.03% 80.25%
Regeneron Pharmaceuticals Inc. 85.39% 84.97% 84.65% 84.83% 86.65% 86.85% 86.84% 86.82% 87.98% 88.21% 89.72% 90.05%
Thermo Fisher Scientific Inc. 44.42% 46.63% 48.37% 50.08% 51.05% 51.29% 51.47% 49.67% 47.31% 45.39% 44.30% 44.35%
Vertex Pharmaceuticals Inc. 88.00% 88.13% 87.95% 88.06% 87.94% 87.89% 88.06% 88.14% 88.01% 87.71% 87.24% 86.84%

Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).

1 Q3 2022 Calculation
Gross profit margin = 100 × (Gross profitQ3 2022 + Gross profitQ2 2022 + Gross profitQ1 2022 + Gross profitQ4 2021) ÷ (RevenueQ3 2022 + RevenueQ2 2022 + RevenueQ1 2022 + RevenueQ4 2021)
= 100 × (2,039,000 + 2,105,100 + 1,777,900 + 2,073,700) ÷ (2,508,500 + 2,589,100 + 2,531,800 + 2,733,800) = 77.15%

2 Click competitor name to see calculations.

Profitability ratio Description The company
Gross profit margin Gross profit margin indicates the percentage of revenue available to cover operating and other expenditures. Biogen Inc. gross profit margin ratio deteriorated from Q1 2022 to Q2 2022 and from Q2 2022 to Q3 2022.

Operating Profit Margin

Biogen Inc., operating profit margin calculation (quarterly data)

Microsoft Excel
Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017
Selected Financial Data (US$ in thousands)
Income from operations 1,315,100 840,900 610,700 587,100 794,000 485,700 973,900 (330,700) 1,086,400 1,974,500 1,819,900 1,777,700 1,806,300 1,955,900 1,502,700 1,443,100 1,697,600 1,213,200 1,534,700 1,465,800 1,653,500 1,200,600 1,024,300
Revenue 2,508,500 2,589,100 2,531,800 2,733,800 2,778,900 2,775,000 2,694,000 2,852,600 3,376,100 3,681,600 3,534,300 3,671,300 3,600,100 3,616,700 3,489,800 3,526,300 3,439,000 3,356,500 3,131,100 3,307,000 3,077,800 3,078,400 2,810,700
Profitability Ratio
Operating profit margin1 32.36% 26.64% 22.90% 25.87% 17.32% 18.94% 29.39% 33.84% 46.68% 50.93% 51.03% 48.98% 47.13% 46.90% 42.40% 43.77% 44.67% 45.58% 46.49% 43.54%
Benchmarks
Operating Profit Margin, Competitors2
AbbVie Inc. 30.59% 30.33% 32.68% 31.89% 30.09% 28.95% 23.63% 24.81% 28.45% 30.17% 39.86% 39.03%
Amgen Inc. 39.31% 38.04% 32.78% 31.44% 30.14% 30.72% 37.23% 37.70% 38.59% 39.76% 41.89% 43.57%
Bristol-Myers Squibb Co. 19.04% 18.19% 16.79% 15.91% -15.73% -17.02% -19.19% -21.60% 9.27% 11.67% 16.30% 22.62%
Eli Lilly & Co. 24.65% 25.50% 25.94% 22.45% 23.17% 21.81% 22.06% 24.69% 23.55% 24.48% 25.64% 22.29%
Gilead Sciences Inc. 22.39% 25.78% 26.56% 36.72% 42.79% 37.20% 18.07% 16.72% 11.01% -4.40% 19.89% 19.38%
Johnson & Johnson 23.89% 23.47% 23.76% 24.95% 24.69% 25.23% 24.10% 23.60% 24.30% 24.64% 25.62% 24.15%
Merck & Co. Inc. 30.66% 33.04% 28.85% 25.74% 14.07% 10.64% 14.02% 16.47% 26.87% 25.40% 25.49% 24.77%
Pfizer Inc. 33.59% 30.37% 26.12% 23.91% 24.67% 24.12% 21.20% 19.47% 21.17% 21.17% 24.20% 25.46%
Regeneron Pharmaceuticals Inc. 45.45% 48.19% 55.08% 55.67% 55.19% 53.94% 43.37% 42.09% 37.43% 34.64% 30.45% 28.10%
Thermo Fisher Scientific Inc. 20.54% 22.51% 23.83% 25.57% 27.04% 28.00% 27.68% 24.19% 20.90% 17.05% 17.86% 17.99%
Vertex Pharmaceuticals Inc. 47.72% 48.85% 36.93% 36.73% 37.17% 33.93% 47.14% 46.03% 44.43% 38.67% 34.05% 28.77%

Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).

1 Q3 2022 Calculation
Operating profit margin = 100 × (Income from operationsQ3 2022 + Income from operationsQ2 2022 + Income from operationsQ1 2022 + Income from operationsQ4 2021) ÷ (RevenueQ3 2022 + RevenueQ2 2022 + RevenueQ1 2022 + RevenueQ4 2021)
= 100 × (1,315,100 + 840,900 + 610,700 + 587,100) ÷ (2,508,500 + 2,589,100 + 2,531,800 + 2,733,800) = 32.36%

2 Click competitor name to see calculations.

Profitability ratio Description The company
Operating profit margin A profitability ratio calculated as operating income divided by revenue. Biogen Inc. operating profit margin ratio improved from Q1 2022 to Q2 2022 and from Q2 2022 to Q3 2022.

Net Profit Margin

Biogen Inc., net profit margin calculation (quarterly data)

Microsoft Excel
Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017
Selected Financial Data (US$ in thousands)
Net income attributable to Biogen Inc. 1,134,700 1,058,000 303,800 368,200 329,200 448,500 410,200 357,900 701,500 1,542,100 1,399,100 1,439,700 1,545,900 1,494,100 1,408,800 946,800 1,444,400 866,600 1,172,900 (297,400) 1,226,100 862,800 747,600
Revenue 2,508,500 2,589,100 2,531,800 2,733,800 2,778,900 2,775,000 2,694,000 2,852,600 3,376,100 3,681,600 3,534,300 3,671,300 3,600,100 3,616,700 3,489,800 3,526,300 3,439,000 3,356,500 3,131,100 3,307,000 3,077,800 3,078,400 2,810,700
Profitability Ratio
Net profit margin1 27.64% 19.37% 13.40% 14.17% 13.93% 16.40% 23.89% 29.76% 35.63% 40.91% 40.76% 40.96% 37.91% 37.62% 33.79% 32.93% 24.08% 23.06% 23.54% 20.69%
Benchmarks
Net Profit Margin, Competitors2
AbbVie Inc. 23.19% 22.04% 22.00% 20.54% 13.66% 12.40% 10.28% 10.08% 18.16% 19.20% 24.77% 23.69%
Amgen Inc. 27.88% 26.73% 23.42% 24.25% 23.03% 23.80% 29.60% 29.97% 30.91% 31.53% 33.64% 35.32%
Bristol-Myers Squibb Co. 14.29% 14.04% 13.31% 15.08% -11.89% -11.44% -14.53% -21.20% -0.11% -1.61% 3.08% 13.15%
Eli Lilly & Co. 20.63% 19.58% 20.90% 19.71% 21.52% 22.71% 23.91% 25.24% 24.01% 24.48% 23.97% 37.27%
Gilead Sciences Inc. 12.44% 15.22% 16.60% 23.05% 27.21% 19.62% 1.19% 0.51% 5.56% -1.18% 22.17% 24.35%
Johnson & Johnson 19.95% 19.21% 20.90% 22.26% 19.55% 19.92% 17.95% 17.82% 21.01% 18.86% 20.75% 18.42%
Merck & Co. Inc. 25.88% 29.00% 26.27% 26.79% 15.09% 11.83% 15.09% 14.72% 24.33% 22.20% 21.10% 21.01%
Pfizer Inc. 29.81% 28.94% 27.01% 27.04% 28.77% 23.86% 24.03% 22.95% 18.59% 31.31% 32.32% 31.45%
Regeneron Pharmaceuticals Inc. 39.17% 39.97% 48.06% 50.25% 51.65% 50.11% 43.53% 41.35% 38.28% 37.30% 28.56% 26.91%
Thermo Fisher Scientific Inc. 15.92% 17.37% 18.49% 19.70% 21.93% 22.47% 22.08% 19.79% 17.12% 14.12% 14.31% 14.47%
Vertex Pharmaceuticals Inc. 37.62% 38.26% 30.84% 30.92% 30.52% 29.80% 43.06% 43.70% 44.91% 38.51% 31.35% 28.27%

Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).

1 Q3 2022 Calculation
Net profit margin = 100 × (Net income attributable to Biogen Inc.Q3 2022 + Net income attributable to Biogen Inc.Q2 2022 + Net income attributable to Biogen Inc.Q1 2022 + Net income attributable to Biogen Inc.Q4 2021) ÷ (RevenueQ3 2022 + RevenueQ2 2022 + RevenueQ1 2022 + RevenueQ4 2021)
= 100 × (1,134,700 + 1,058,000 + 303,800 + 368,200) ÷ (2,508,500 + 2,589,100 + 2,531,800 + 2,733,800) = 27.64%

2 Click competitor name to see calculations.

Profitability ratio Description The company
Net profit margin An indicator of profitability, calculated as net income divided by revenue. Biogen Inc. net profit margin ratio improved from Q1 2022 to Q2 2022 and from Q2 2022 to Q3 2022.

Return on Equity (ROE)

Biogen Inc., ROE calculation (quarterly data)

Microsoft Excel
Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017
Selected Financial Data (US$ in thousands)
Net income attributable to Biogen Inc. 1,134,700 1,058,000 303,800 368,200 329,200 448,500 410,200 357,900 701,500 1,542,100 1,399,100 1,439,700 1,545,900 1,494,100 1,408,800 946,800 1,444,400 866,600 1,172,900 (297,400) 1,226,100 862,800 747,600
Total Biogen Inc. shareholders’ equity 12,775,500 11,872,500 11,242,300 10,896,200 10,429,900 10,751,900 10,682,200 10,700,300 10,758,500 11,308,700 12,546,900 13,343,200 13,995,900 12,952,900 13,829,900 13,039,600 13,766,600 12,260,900 14,053,700 12,612,800 12,860,500 11,585,200 11,479,000
Profitability Ratio
ROE1 22.42% 17.34% 12.90% 14.28% 14.82% 17.84% 28.19% 37.39% 47.24% 52.41% 46.85% 44.13% 38.55% 40.87% 33.74% 33.98% 23.15% 24.21% 21.09% 20.13%
Benchmarks
ROE, Competitors2
AbbVie Inc. 83.83% 86.24% 76.64% 74.91% 55.60% 53.01% 37.63% 35.30% 48.34% 47.30%
Amgen Inc. 187.11% 271.85% 624.78% 87.96% 68.26% 69.67% 75.91% 77.20% 67.09% 68.48% 80.92% 81.07%
Bristol-Myers Squibb Co. 20.44% 20.30% 19.79% 19.46% -14.52% -13.80% -16.54% -23.84% -0.09% -1.15% 1.91% 6.66%
Eli Lilly & Co. 59.91% 66.61% 65.69% 62.16% 76.99% 94.20% 88.31% 109.79% 115.45% 137.26% 179.72% 319.09%
Gilead Sciences Inc. 15.82% 20.44% 22.66% 29.55% 34.44% 26.20% 1.59% 0.68% 7.27% -1.43% 22.49% 23.91%
Johnson & Johnson 25.68% 24.05% 26.54% 28.20% 25.44% 25.53% 22.96% 23.25% 26.35% 24.11% 28.01% 25.42%
Merck & Co. Inc. 34.32% 38.34% 34.68% 34.17% 20.10% 16.73% 26.08% 27.91% 39.47% 37.91% 38.72% 37.99%
Pfizer Inc. 32.14% 33.61% 30.29% 28.47% 26.28% 18.86% 16.23% 15.21% 12.22% 22.05% 24.21% 25.77%
Regeneron Pharmaceuticals Inc. 25.05% 27.49% 39.84% 43.03% 40.53% 41.02% 33.43% 31.86% 31.17% 32.94% 18.79% 19.08%
Thermo Fisher Scientific Inc. 16.15% 17.59% 18.56% 18.94% 22.13% 23.32% 22.60% 18.47% 15.33% 12.41% 12.85% 12.45%
Vertex Pharmaceuticals Inc. 25.12% 26.77% 22.47% 23.19% 22.83% 21.66% 30.76% 31.22% 33.08% 27.67% 23.38% 19.34%

Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).

1 Q3 2022 Calculation
ROE = 100 × (Net income attributable to Biogen Inc.Q3 2022 + Net income attributable to Biogen Inc.Q2 2022 + Net income attributable to Biogen Inc.Q1 2022 + Net income attributable to Biogen Inc.Q4 2021) ÷ Total Biogen Inc. shareholders’ equity
= 100 × (1,134,700 + 1,058,000 + 303,800 + 368,200) ÷ 12,775,500 = 22.42%

2 Click competitor name to see calculations.

Profitability ratio Description The company
ROE A profitability ratio calculated as net income divided by shareholders’ equity. Biogen Inc. ROE improved from Q1 2022 to Q2 2022 and from Q2 2022 to Q3 2022.

Return on Assets (ROA)

Biogen Inc., ROA calculation (quarterly data)

Microsoft Excel
Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017
Selected Financial Data (US$ in thousands)
Net income attributable to Biogen Inc. 1,134,700 1,058,000 303,800 368,200 329,200 448,500 410,200 357,900 701,500 1,542,100 1,399,100 1,439,700 1,545,900 1,494,100 1,408,800 946,800 1,444,400 866,600 1,172,900 (297,400) 1,226,100 862,800 747,600
Total assets 24,854,200 25,081,400 23,614,400 23,877,300 23,806,700 24,470,400 23,854,700 24,618,900 24,934,100 25,511,800 26,119,200 27,234,300 27,484,000 26,287,600 26,445,500 25,288,900 25,492,200 23,952,900 26,090,100 23,652,600 23,073,200 21,759,000 21,195,900
Profitability Ratio
ROA1 11.53% 8.21% 6.14% 6.52% 6.49% 7.84% 12.63% 16.25% 20.38% 23.23% 22.51% 21.62% 19.63% 20.14% 17.65% 17.52% 12.50% 12.39% 11.36% 10.73%
Benchmarks
ROA, Competitors2
AbbVie Inc. 9.49% 8.83% 8.71% 7.88% 5.06% 4.50% 3.43% 3.07% 4.93% 4.65% 9.25% 8.84%
Amgen Inc. 10.73% 11.09% 9.67% 9.63% 8.63% 9.61% 11.33% 11.54% 11.37% 11.23% 12.45% 13.13%
Bristol-Myers Squibb Co. 6.80% 6.59% 6.07% 6.40% -4.87% -4.58% -5.53% -7.61% -0.04% -0.44% 0.74% 2.65%
Eli Lilly & Co. 12.71% 12.09% 13.06% 11.44% 12.39% 12.70% 13.01% 13.28% 12.68% 13.39% 13.46% 21.17%
Gilead Sciences Inc. 5.33% 6.58% 7.16% 9.16% 11.02% 7.59% 0.45% 0.18% 2.08% -0.46% 8.31% 8.74%
Johnson & Johnson 10.94% 10.33% 11.12% 11.47% 9.98% 10.07% 8.76% 8.41% 9.95% 9.59% 11.07% 9.59%
Merck & Co. Inc. 14.25% 15.48% 13.29% 12.35% 7.70% 6.14% 7.73% 7.72% 12.83% 11.56% 11.95% 11.66%
Pfizer Inc. 15.32% 15.01% 13.58% 12.11% 11.10% 7.78% 7.01% 6.23% 4.46% 7.97% 9.47% 9.72%
Regeneron Pharmaceuticals Inc. 19.40% 20.90% 30.11% 31.75% 29.55% 28.88% 22.53% 20.47% 19.62% 20.68% 14.46% 14.29%
Thermo Fisher Scientific Inc. 7.77% 8.21% 8.20% 8.12% 11.64% 12.70% 12.02% 9.23% 7.62% 6.02% 6.25% 6.33%
Vertex Pharmaceuticals Inc. 19.59% 20.50% 17.19% 17.44% 17.25% 16.30% 22.80% 23.07% 23.81% 20.37% 16.99% 14.15%

Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).

1 Q3 2022 Calculation
ROA = 100 × (Net income attributable to Biogen Inc.Q3 2022 + Net income attributable to Biogen Inc.Q2 2022 + Net income attributable to Biogen Inc.Q1 2022 + Net income attributable to Biogen Inc.Q4 2021) ÷ Total assets
= 100 × (1,134,700 + 1,058,000 + 303,800 + 368,200) ÷ 24,854,200 = 11.53%

2 Click competitor name to see calculations.

Profitability ratio Description The company
ROA A profitability ratio calculated as net income divided by total assets. Biogen Inc. ROA improved from Q1 2022 to Q2 2022 and from Q2 2022 to Q3 2022.